The global leader in rabies vaccines, the serum-free iterative rabies vaccine of AIM Vaccine has submitted a pre-application for marketing registration
- Written by The Bulletin
HONG KONG SAR - Media OutReach Newswire - 18 November 2024 - AIM Vaccine (06660.HK), the world's second largest supplier of rabies vaccines, announced on 17th November that The pre-application for marketing registration of the iterative serum-free rabies vaccine independently developed by the Company has been submitted to the National Medical Products Administration recently.
